ClearPoint Neuro, Inc.

ClearPoint Neuro, Inc. Annual Report - A Closer Look for Investors

Unlock a clear understanding of ClearPoint Neuro, Inc.'s performance for the year ending December 31, 2025. This summary cuts through complex financial language, offering investors a straightforward look at the company's business, financial health, key achievements, and future outlook.

Business Overview: Who is ClearPoint Neuro? ClearPoint Neuro is a medical technology company focused on advanced navigation and delivery systems for the brain and spine. Its core mission is to improve patient outcomes in neurological procedures by providing precise, image-guided solutions. The company's flagship ClearPoint® system, along with technologies like SmartFlow® and SmartFrame®, empowers neurosurgeons to accurately target specific brain areas for drug delivery, biopsy, or device placement, often using MRI guidance. ClearPoint Neuro primarily serves hospitals and research institutions, addressing conditions such as Parkinson's disease, essential tremor, and certain brain tumors.

As a "smaller reporting company," ClearPoint Neuro benefits from scaled-down disclosure requirements compared to larger corporations due to its market capitalization. This means investors may find less granular detail in some financial reports. Additionally, the company's stock can sometimes experience higher volatility, reflecting its size and focus on specialized markets.

Financial Performance: Financial Snapshot (Year Ended December 31, 2025): ClearPoint Neuro reported total revenue of $52.5 million, a 22% increase from the previous year. This growth primarily stemmed from strong adoption of their ClearPoint® system and increased service revenue from their biologics and drug delivery programs. Despite this revenue growth, the company recorded a net loss of $12.8 million for the year. This loss largely resulted from significant investments in research and development (R&D) for next-generation platforms and clinical trial support. Gross margin reached 65%, underscoring the high-value nature of their specialized products.

As of December 31, 2025, the company held a healthy cash and cash equivalents balance of $35.1 million, providing liquidity for ongoing operations and R&D initiatives. Approximately 29.66 million shares of common stock were outstanding as of March 6, 2026, with a public float market value of roughly $328 million as of June 30, 2025.

Key Achievements & Operational Highlights: ClearPoint Neuro achieved several key milestones and operational successes:

• Product Innovation: The company successfully launched the next iteration of its SmartFrame® Array, which enhances targeting capabilities and reduces procedure times.
• Strategic Partnerships: ClearPoint Neuro deepened collaborations with industry leaders like Siemens, integrating its ClearPoint® system directly into Siemens' MRI platforms for seamless surgical planning. Partnerships with Boston Scientific, Brainlab, and Medtronic also expanded, focusing on co-development and distribution agreements that leverage ClearPoint Neuro's precision delivery capabilities with partners' therapeutic solutions.
• Clinical Progress: The company advanced multiple clinical trials, including a pivotal study for targeted gene therapy delivery in Parkinson's disease. Initial data from this study showed promising safety and efficacy profiles.
• Global Expansion: ClearPoint Neuro expanded its commercial presence into two new European markets, contributing to a 15% increase in international revenue.

Risk Factors: Challenges and Risks: ClearPoint Neuro navigates several key risks. Intense competition from larger medical device companies with greater resources could threaten its market share. The company also faces stringent regulatory hurdles for product approvals and ongoing compliance, which can be costly and time-consuming. Dependence on a few key products means that any issues with the ClearPoint® system could significantly impact financial performance. Furthermore, the success of its biologics and drug delivery programs heavily relies on the successful outcomes of clinical trials and subsequent market adoption, both inherently uncertain. While managed, supply chain disruptions remain a potential concern for manufacturing.

Management's Discussion and Analysis (MD&A Highlights): Management attributes the 22% revenue growth to increased adoption of the ClearPoint® system and expanded service revenue from their biologics and drug delivery programs. This reflects the successful execution of their commercial strategy and strategic partnerships.

The reported net loss of $12.8 million primarily stems from substantial investments in research and development (R&D). These investments aim to advance next-generation platforms and support critical clinical trials, which management deems essential for long-term growth and market expansion. The 65% gross margin underscores the value proposition and specialized nature of the company's products.

Operational highlights, including the launch of the SmartFrame® Array, deepened collaborations with industry leaders, and progress in clinical trials, demonstrate ClearPoint Neuro's commitment to innovation and market leadership. Management continues to balance growth initiatives with prudent financial management, leveraging its cash position to fund strategic R&D and market expansion efforts.

Financial Health (Debt, Cash, and Liquidity): As of December 31, 2025, ClearPoint Neuro maintained a strong liquidity position, holding $35.1 million in cash and cash equivalents. Management believes this is sufficient to fund ongoing operations, planned capital expenditures, and research and development initiatives for the foreseeable future. Equity primarily forms the company's capital structure. Management continuously monitors its capital resources and cash flow to ensure financial flexibility and support strategic objectives, including potential future investments and collaborations. The public float market value of approximately $328 million provides a basis for market liquidity for its shares.

Future Outlook & Strategy: Looking ahead, ClearPoint Neuro's strategy rests on three core pillars:

1. Expanding Indications: The company invests in R&D to broaden its technology's application to new neurological conditions and therapeutic areas, including advanced cell and gene therapies.
2. Platform Innovation: It develops next-generation navigation and delivery platforms that offer even greater precision, automation, and integration with emerging neurosurgical techniques.
3. Strategic Collaborations: ClearPoint Neuro continues to forge and strengthen partnerships with pharmaceutical and medical device companies, integrating its technology into broader treatment paradigms and accelerating market penetration.

The company anticipates continued revenue growth in 2026, driven by new product launches and expanded clinical trial support. However, profitability may remain challenged in the short term due to ongoing R&D investments. Management remains optimistic about its technology's long-term potential to revolutionize neurosurgery and improve patient lives.

Competitive Position: ClearPoint Neuro operates in a highly competitive medical technology market, facing competition from larger, more established medical device companies with greater financial, technical, and marketing resources. Despite this, the company maintains a strong competitive position by specializing in advanced, image-guided navigation and delivery systems for the brain and spine, offering precise and integrated solutions.

Its proprietary ClearPoint® system, SmartFlow®, and SmartFrame® technologies provide differentiation through their unique ability to enable accurate targeting with MRI. Strategic partnerships with industry leaders like Siemens, Boston Scientific, Brainlab, and Medtronic further enhance its competitive edge. These collaborations integrate ClearPoint Neuro's technology into broader therapeutic solutions and expand its market reach. The company's focus on niche, high-value applications, particularly in gene and cell therapy delivery, allows it to carve out and defend its market segment against broader competitors.